SHR-4640 is under clinical development by Jiangsu Hengrui Medicine and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SHR-4640’s likelihood of approval (LoA) and phase transition for Liver Failure (Hepatic Insufficiency) took place on 13 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SHR-4640 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SHR-4640 is under development for the treatment of gout, liver failure (hepatic insufficiency) and hyperuricemia. The therapeutic candidate is formulated as tablet and administered orally. The drug candidate acts by targeting human uric acid transporter 1.
Jiangsu Hengrui Medicine overview
Jiangsu Hengrui Medicine (Jiangsu Hengrui) is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes anti-tumor drugs, surgical drugs, contrast agents, angiomyocardiac drugs, and antibiotics. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia. Jiangsu Hengrui has R&D facilities in China, the US and Japan. The company offers products through its sales and distribution network in China, the US, Japan, Germany Switzerland, and Australia. Jiangsu Hengrui is headquartered in Lianyungang, Jiangsu Province, China.
Quick View SHR-4640 LOA Data
|Highest Development Stage|